While BC is typically not considered highly immunogenic compared to other malignancies like lung cancer or melanoma, recent data have shown the benefits of immunotherapy, particularly in the triple-negative subtype (ER/PR and HER2 negative). This evidence concerns the gene ERBB2 and breast cancer.